IDH2 and central nervous system cancer: IDH305 has moved into clinical testing in humans with IDH-mutant glioma, AML/MDS, and other solid tumors, and phase 1 safety data in all tumor types is promising (ClinicalTrials.gov NCT02381886) (83).